Cytosorbents（CTSO）株式概要
サイトソルベント・コーポレーションは、血液浄化技術プラットフォームを用いた医療機器の研究、開発、商業化を米国、ドイツ、および国際的に行っている。 詳細
CTSO Community Fair Values
Create NarrativeSee what 8 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cytosorbents Corporation 競合他社
価格と性能
| 過去の株価 | |
|---|---|
| 現在の株価 | US$0.39 |
| 52週高値 | US$1.22 |
| 52週安値 | US$0.35 |
| ベータ | 1.39 |
| 1ヶ月の変化 | -2.83% |
| 3ヶ月変化 | -34.29% |
| 1年変化 | -62.28% |
| 3年間の変化 | -89.72% |
| 5年間の変化 | -95.00% |
| IPOからの変化 | -99.11% |
最新ニュース
ナラティブ更新 • Jun 16
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).
ナラティブ更新 • Jun 02
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.Recent updates
ナラティブ更新 • Jun 16
CTSO: Nasdaq Extension And Clinical Data Will Support Future Upside Potential
Analysts have reduced their fair value estimate for Cytosorbents from $10.00 to $5.00, citing updated assumptions that now reflect a higher discount rate, more moderate revenue growth expectations, slightly lower profit margin forecasts, and a modestly lower future P/E multiple. What's in the News Nasdaq granted Cytosorbents a 180 day extension, until September 28, 2026, to regain compliance with the minimum US$1.00 bid price requirement for continued listing under Nasdaq Listing Rule 5550(a)(2).ナラティブ更新 • Jun 02
CTSO: Nasdaq Compliance Extension Will Support Future Turnaround Potential
Analysts have reduced their fair value estimate for Cytosorbents from $5.00 to $2.88 as they recalibrate assumptions for revenue growth, profit margins, the discount rate, and the stock's future P/E multiple. What's in the News On April 1, 2026, Cytosorbents received a 180 day extension from Nasdaq until September 28, 2026 to regain compliance with the minimum US$1.00 bid price requirement for continued listing.
ナラティブ更新 • May 15
CTSO: ICU Utilization And Nasdaq Compliance Extension Will Support Future Upside
Analysts have kept the fair value estimate for Cytosorbents steady at $0.75. Modest tweaks to assumptions for the discount rate, revenue growth, profit margin, and future P/E reflect updated views on risk, earnings power, and likely valuation multiples.ナラティブ更新 • Apr 27
CTSO: ICU Adoption And Nasdaq Compliance Efforts Will Support Future Upside
Analysts have maintained their $0.75 price target on Cytosorbents. They cite small adjustments in the discount rate, revenue growth assumptions, and future P/E estimates as they refine their models, while keeping their overall valuation view unchanged.ナラティブ更新 • Apr 11
CTSO: 2025 Revenue Outlook And ICU Adoption Will Support Upside
Analysts have maintained their $0.75 price target for Cytosorbents, citing only modest adjustments to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock’s valuation. What's in the News Nasdaq granted CytoSorbents a 180 day extension, until September 28, 2026, to regain compliance with the US$1.00 minimum bid price requirement for continued listing on the exchange, with the stock remaining listed during this period (Delistings notice).ナラティブ更新 • Mar 28
CTSO: Steady 2025 Outlook And ICU Therapy Progress Will Support Upside
Analysts have held their fair value estimate for Cytosorbents steady, keeping the implied price target unchanged at $0.75. This reflects slightly adjusted views on discount rate, revenue growth and profit margin assumptions, without a clear shift in overall conviction.ナラティブ更新 • Mar 12
CTSO: Steady 2025 Revenue Guidance Will Support Measured Long Term Upside
Analysts have made a modest adjustment to their Cytosorbents price target, citing updated assumptions for discount rate, revenue growth, profit margin, and future P/E. Taken together, these changes leave their fair value estimate broadly unchanged around $0.75.ナラティブ更新 • Feb 26
CTSO: Flat 2025 Outlook And Cost Discipline Will Support Measured Upside
Analysts have slightly adjusted their price target for Cytosorbents to reflect updated assumptions around revenue growth, profit margin and future P/E, while keeping the fair value broadly in line at $0.75. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, the same figure as guidance for the fourth quarter of 2024 (Key Developments).ナラティブ更新 • Feb 09
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Support Upside
Analysts have trimmed their price target on Cytosorbents to reflect a slightly lower assumed discount rate, marginally higher projected revenue growth, improved profit margin expectations, and a modestly lower future P/E multiple. This results in a revised valuation that they see as better aligned with updated assumptions.ナラティブ更新 • Jan 26
CTSO: Cost Cuts And 2026 Cash Flow Break Even Will Shape Outlook
Narrative Update on Cytosorbents Analysts have kept their price target for Cytosorbents steady at US$0.75, citing updated assumptions that reflect slightly lower discount rates, modestly higher projected revenue growth, a stable profit margin outlook, and a small adjustment to expected future P/E levels. What's in the News Cytosorbents issued earnings guidance for the fourth quarter of 2025, with revenue expected to be approximately US$9.2 million, in line with the fourth quarter of 2024 at US$9.2 million (Key Developments).ナラティブ更新 • Jan 10
CTSO: Cost Reductions And 2026 Cash Flow Break Even Will Support Upside
Analysts have updated their price target on Cytosorbents and maintained fair value at US$0.75. They have also fine tuned underlying assumptions such as the discount rate, revenue growth, profit margin and future P/E to reflect revised views on the company’s risk and earnings profile.ナラティブ更新 • Dec 26
CTSO: Cost Cuts And Nasdaq Listing Risk Will Shape Balanced Outlook
Analysts modestly raised their price target on Cytosorbents to reflect a slightly lower discount rate and higher expected future earnings multiples, even as they tempered long term revenue growth assumptions. What's in the News Cytosorbents announced a strategic workforce and cost reduction plan, cutting approximately 10% of its staff and realigning production and operating expenses to target operating cash flow break even by the first quarter of 2026 (Key Developments).ナラティブ更新 • Dec 12
CTSO: Workforce Cuts And FDA Pathway Are Expected To Shape Outlook
Analysts have trimmed their price target on Cytosorbents from approximately 12.84 dollars to 7.96 dollars. This reflects slightly lower long term revenue growth assumptions, a higher perceived risk profile, and only modestly improved profitability expectations.分析記事 • Nov 13
Market Cool On Cytosorbents Corporation's (NASDAQ:CTSO) Revenues Pushing Shares 31% Lower
To the annoyance of some shareholders, Cytosorbents Corporation ( NASDAQ:CTSO ) shares are down a considerable 31% in...分析記事 • Nov 08
Is Cytosorbents (NASDAQ:CTSO) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...ナラティブ更新 • Aug 10
FDA And Health Canada Approval Will Spur ICU Solutions
Cytosorbents’ consensus price target has been raised from $5.00 to $7.00, reflecting improved profitability with net profit margin rising to 12.34% and a more attractive future P/E of 74.11x. What's in the News New studies demonstrate early and intensive CytoSorb® therapy significantly improves clinical outcomes for sepsis and septic shock patients, with peer-reviewed data showing increased survival rates when used intensively and early.分析記事 • Aug 09
Does Cytosorbents (NASDAQ:CTSO) Have A Healthy Balance Sheet?
NasdaqCM:CTSO 1 Year Share Price vs Fair Value Explore Cytosorbents's Fair Values from the Community and select yours...分析記事 • Jul 02
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 54% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders would be excited to see that the share price has had a great...
新しいナラティブ • Apr 11
FDA And Health Canada Decisions Will Advance DrugSorb-ATR Launch
Regulatory decisions on DrugSorb-ATR could drive significant revenue growth, especially in the U.S. and Canada, with a large market opportunity.分析記事 • Jan 17
Further Upside For Cytosorbents Corporation (NASDAQ:CTSO) Shares Could Introduce Price Risks After 28% Bounce
Cytosorbents Corporation ( NASDAQ:CTSO ) shareholders are no doubt pleased to see that the share price has bounced 28...分析記事 • Oct 01
The Market Lifts Cytosorbents Corporation (NASDAQ:CTSO) Shares 43% But It Can Do More
Despite an already strong run, Cytosorbents Corporation ( NASDAQ:CTSO ) shares have been powering on, with a gain of...分析記事 • Jul 04
Investors Continue Waiting On Sidelines For Cytosorbents Corporation (NASDAQ:CTSO)
With a price-to-sales (or "P/S") ratio of 1.3x Cytosorbents Corporation ( NASDAQ:CTSO ) may be sending bullish signals...分析記事 • Mar 16
Health Check: How Prudently Does Cytosorbents (NASDAQ:CTSO) Use Debt?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...分析記事 • Jan 06
Take Care Before Jumping Onto Cytosorbents Corporation (NASDAQ:CTSO) Even Though It's 28% Cheaper
Unfortunately for some shareholders, the Cytosorbents Corporation ( NASDAQ:CTSO ) share price has dived 28% in the last...株主還元
| CTSO | US Medical Equipment | US 市場 | |
|---|---|---|---|
| 7D | -4.5% | -6.0% | 0.2% |
| 1Y | -62.3% | -21.7% | 19.6% |
業界別リターン: CTSO過去 1 年間で-21.7 % の収益を上げたUS Medical Equipment業界を下回りました。
リターン対市場: CTSOは、過去 1 年間で19.6 % のリターンを上げたUS市場を下回りました。
価格変動
| CTSO volatility | |
|---|---|
| CTSO Average Weekly Movement | 13.2% |
| Medical Equipment Industry Average Movement | 8.4% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.2% |
安定した株価: CTSOの株価は、 US市場と比較して過去 3 か月間で変動しています。
時間の経過による変動: CTSOの weekly volatility ( 13% ) は過去 1 年間安定していますが、依然としてUSの株式の 75% よりも高くなっています。
会社概要
| 設立 | 従業員 | CEO（最高経営責任者 | ウェブサイト |
|---|---|---|---|
| 1997 | 129 | Phil Chan | www.cytosorbents.com |
サイトソルベント・コーポレーションは、血液浄化技術プラットフォームを用いた医療機器の研究、開発、商業化を米国、ドイツ、および国際的に行っている。同社の主力製品であるCytoSorbは、一般的な重症疾患におけるサイトカインストーム、肝不全におけるビリルビン、外傷や重症疾患におけるミオグロビン、心臓外科手術用途における炎症性メディエーターや血液希釈剤を減少させ、また心臓胸部外科手術用途における抗血栓薬や炎症性メディエーターを除去するための体外式血液浄化カートリッジである。また、血液希釈剤によるハイリスク手術での周術期出血の重症度を軽減する治験用デバイスであるDrugSorb-ATR抗血栓除去システム、生体外臓器灌流システムで使用されるサイトカインやその他の炎症性メディエーターを減少させるECOS-300CYも開発している；VetResQは、敗血症性ショック、中毒性ショック症候群、毒素を介する疾患、膵炎、外傷、肝不全、熱中症、肺損傷などの治療に用いられる幅広いスペクトルの血液浄化吸着剤であり、PuriFiは血液浄化療法用の先進的な血液灌流ポンプである。さらに、血漿および全血中の抗A抗体および抗B抗体を減少させる血液浄化技術プラットフォームであるHemoDefend-BGAを開発している。以前はMedaSorb Technologies Corporationとして知られていたが、2010年5月にCytosorbents Corporationに社名を変更した。サイトソルベント・コーポレーションは1997年に設立され、ニュージャージー州プリンストンに本社を置いている。
Cytosorbents Corporation 基礎のまとめ
| CTSO 基礎統計学 | |
|---|---|
| 時価総額 | US$23.86m |
| 収益（TTM） | -US$11.85m |
| 売上高(TTM) | US$37.20m |
0.7x
P/Sレシオ-2.1x
PER（株価収益率CTSO は割高か？
公正価値と評価分析を参照収益と収入
| CTSO 損益計算書（TTM） | |
|---|---|
| 収益 | US$37.20m |
| 売上原価 | US$10.79m |
| 売上総利益 | US$26.41m |
| その他の費用 | US$38.26m |
| 収益 | -US$11.85m |
直近の収益報告
Mar 31, 2026
次回決算日
該当なし
| 一株当たり利益（EPS） | -0.19 |
| グロス・マージン | 71.01% |
| 純利益率 | -31.85% |
| 有利子負債／自己資本比率 | 773.0% |
CTSO の長期的なパフォーマンスは？
過去の実績と比較を見る企業分析と財務データの現状
| データ | 最終更新日（UTC時間） |
|---|---|
| 企業分析 | 2026/07/14 15:57 |
| 終値 | 2026/07/14 00:00 |
| 収益 | 2026/03/31 |
| 年間収益 | 2025/12/31 |
データソース
企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。
| パッケージ | データ | タイムフレーム | 米国ソース例 |
|---|---|---|---|
| 会社財務 | 10年 |
| |
| アナリストのコンセンサス予想 | +プラス3年 |
|
|
| 市場価格 | 30年 |
| |
| 所有権 | 10年 |
| |
| マネジメント | 10年 |
| |
| 主な進展 | 10年 |
|
* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。
特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。
分析モデルとスノーフレーク
このレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。
シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。
業界およびセクターの指標
私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。
アナリスト筋
Cytosorbents Corporation 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5
| アナリスト | 機関 |
|---|---|
| Sean Lee | H.C. Wainwright & Co. |
| Anthony Petrone | Jefferies LLC |
| Danielle Antalffy | Leerink Partners LLC |